Human Papillomaviruses 16 and 18 E6 Oncoprotein Detection Test in Primary Oropharyngeal Carcinomas and Metastatic Lymph Nodes: A Cross-Sectional Study.
Humans
Cross-Sectional Studies
Female
Male
Oropharyngeal Neoplasms
/ virology
Middle Aged
Oncogene Proteins, Viral
/ analysis
Aged
Papillomavirus Infections
/ complications
Adult
Repressor Proteins
/ analysis
Sensitivity and Specificity
Lymphatic Metastasis
/ diagnosis
Human papillomavirus 18
/ genetics
Human papillomavirus 16
DNA-Binding Proteins
/ analysis
Biomarkers, Tumor
/ analysis
Aged, 80 and over
Human Papillomavirus Viruses
E6 oncoprotein
HPV
HPV-DNA
Lateral flow immunochromatographic assay
Oropharyngeal cancer
P16
Squamous cell carcinoma
Journal
Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
received:
13
08
2024
accepted:
24
09
2024
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
epublish
Résumé
Accuracy in the diagnosis of HPV-associated oropharyngeal carcinoma (OPSCC) of a rapid, low-cost lateral flow immunochromatographic assay for detecting E6 oncoprotein of HPV-16 and HPV-18 was previously evaluated in a small pilot study. This cross-sectional study aimed to assess on a large case series the sensitivity and specificity of E6 oncoprotein as a diagnostic marker for HPV-associated carcinogenesis in OPSCC. 137 consecutive patients with histologically confirmed OPSCC were enrolled in two hospitals in Northeast Italy. HPV status was determined by PCR for HPV DNA and p16 Of the 137 OPSCC cases, 68 (49.6%) were HPV-associated, testing positive for both high-risk HPV-DNA and p16 The low-cost lateral flow immunochromatographic assay for detecting HPV16/18 E6 oncoproteins confirmed high accuracy for identifying HPV-associated OPSCC, particularly in primary tumors, suggesting its potential as a valuable diagnostic tool in clinical practice. Its rapid diagnostic capability could significantly accelerate the process of treatment decision-making, enhancing the timely management of patients.
Identifiants
pubmed: 39404976
doi: 10.1007/s12105-024-01713-7
pii: 10.1007/s12105-024-01713-7
doi:
Substances chimiques
Oncogene Proteins, Viral
0
E6 protein, Human papillomavirus type 16
0
E6 protein, Human papillomavirus type 18
0
Repressor Proteins
0
DNA-Binding Proteins
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
101Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Lechner M, Liu J, Masterson L, Fenton TR (2022) HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 19:306–327
doi: 10.1038/s41571-022-00603-7
pubmed: 35105976
pmcid: 8805140
Boscolo-Rizzo P, Polesel J, Del Mistro A, Fratta E, Lazzarin C, Menegaldo A et al (2023) Rising trend in the prevalence of HPV-driven oropharyngeal squamous cell carcinoma during 2000–2022 in Northeastern Italy: implication for Using p16INK4a as a Surrogate Marker for HPV-Driven Carcinogenesis. Cancers 15:2643
doi: 10.3390/cancers15092643
pubmed: 37174107
pmcid: 10177129
Mehanna H, Alemany L, von Buchwald C (2024) Advances in testing for human papillomavirus-mediated head and neck cancer. Curr Opin Oncol 36:143–146
doi: 10.1097/CCO.0000000000001029
pubmed: 38506408
pmcid: 10990024
Boscolo-Rizzo P, Pawlita M, Holzinger D (2016) From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treat Rev 42:24–29
doi: 10.1016/j.ctrv.2015.10.009
pubmed: 26547133
Bussu F, Ragin C, Boscolo-Rizzo P, Rizzo D, Gallus R, Delogu G et al (2019) HPV as a marker for molecular characterization in head and neck oncology: looking for a standardization of clinical use and of detection method(s) in clinical practice. Head Neck 41:1104–1111
doi: 10.1002/hed.25591
pubmed: 30747478
Simoens C, Gheit T, Ridder R, Gorbaslieva I, Holzinger D, Lucas E et al (2022) Accuracy of high-risk HPV DNA PCR, p16(INK4a) immunohistochemistry or the combination of both to diagnose HPV-driven oropharyngeal cancer. BMC Infect Dis 22:676
doi: 10.1186/s12879-022-07654-2
pubmed: 35933382
pmcid: 9357318
Boscolo-Rizzo P, Dietz A (2017) The AJCC/UICC eighth edition for staging head and neck cancers: Is it wise to de-escalate treatment regimens in p16-positive oropharyngeal cancer patients? Int J Cancer 141:1490–1491
Nauta IH, Rietbergen MM, Van Bokhoven AA, Bloemena E, Lissenberg-Witte BI, Heideman DA, de Jong RB, Brakenhoff RH, Leemans CR (2018) Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing. Ann Oncol Off J Eur Soc Med Oncol. 29:1273–1279
doi: 10.1093/annonc/mdy060
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M et al (2023) Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): a multicentre, multinational, individual patient data analysis. Lancet Oncol 24:239–251
doi: 10.1016/S1470-2045(23)00013-X
pubmed: 36796393
Bussu F, Muresu N, Crescio C, Gallus R, Rizzo D, Cossu A et al (2022) Low prevalence of HPV related oropharyngeal carcinogenesis in Northern Sardinia. Cancers 14:4205
doi: 10.3390/cancers14174205
pubmed: 36077741
pmcid: 9454854
Mena M, Taberna M, Tous S, Marquez S, Clavero O, Quiros B et al (2018) Double positivity for HPV-DNA/p16ink4a is the biomarker with strongest diagnostic accuracy and prognostic value for human papillomavirus related oropharyngeal cancer patients. Oral Oncol 78:137–144
doi: 10.1016/j.oraloncology.2018.01.010
pubmed: 29496041
Chioreanu A, Balica NC, Mot CI, Bugari R, Morar R, Baderca F et al (2024) A retrospective analysis from western romania comparing the treatment and survivability of p16-positive versus p16-negative oropharyngeal cancer. Cancers 16:945
doi: 10.3390/cancers16050945
pubmed: 38473308
pmcid: 10930542
Karp EE, Yin LX, Moore EJ, Elias AJ, O’Byrne TJ, Glasgow AE et al (2021) Barriers to obtaining a timely diagnosis in human papillomavirus-associated oropharynx cancer. Otolaryngol-Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg 165:300–308
doi: 10.1177/0194599820982662
Caudell JJ, Gillison ML, Maghami E, Spencer S, Pfister DG, Adkins D et al (2022) NCCN Guidelines® insights: head and neck cancers, version 1.2022. J Natl Compr Cancer Netw JNCCN 20:224–234
doi: 10.6004/jnccn.2022.0016
pubmed: 35276673
Wiest T, Schwarz E, Enders C, Flechtenmacher C, Bosch FX (2002) Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21:1510–1517
doi: 10.1038/sj.onc.1205214
pubmed: 11896579
Lindquist D, Romanitan M, Hammarstedt L, Näsman A, Dahlstrand H, Lindholm J et al (2007) Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Mol Oncol 1:350–355
doi: 10.1016/j.molonc.2007.08.005
pubmed: 19383307
pmcid: 5543872
Menegaldo A, Schroeder L, Holzinger D, Tirelli G, Dal Cin E, Tofanelli M et al (2021) Detection of HPV16/18 E6 oncoproteins in head and neck squamous cell carcinoma using a protein immunochromatographic assay. Laryngoscope 131:1042–1048
doi: 10.1002/lary.29184
pubmed: 33103777
Nobre RJ, de Almeida LP, Martins TC (2008) Complete genotyping of mucosal human papillomavirus using a restriction fragment length polymorphism analysis and an original typing algorithm. J Clin Virol Off Publ Pan Am Soc Clin Virol 42:13–21
doi: 10.1016/j.jcv.2007.11.021
Mariano VS, Lorenzi AT, Scapulatempo-Neto C, Stein MD, Resende JCP, Antoniazzi M et al (2016) A low-cost HPV Immunochromatographic assay to detect high-grade cervical intraepithelial neoplasia. PLoS ONE 11:e0164892
doi: 10.1371/journal.pone.0164892
pubmed: 27764154
pmcid: 5072685
Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L et al (2015) STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. BMJ 351:h5527
doi: 10.1136/bmj.h5527
pubmed: 26511519
pmcid: 4623764
Murphy CT, Galloway TJ, Handorf EA, Wang L, Mehra R, Flieder DB et al (2015) Increasing time to treatment initiation for head and neck cancer: an analysis of the National Cancer Database. Cancer 121:1204–1213
doi: 10.1002/cncr.29191
pubmed: 25490875
Polesel J, Furlan C, Birri S, Giacomarra V, Vaccher E, Grando G et al (2017) The impact of time to treatment initiation on survival from head and neck cancer in north-eastern Italy. Oral Oncol 67:175–182
doi: 10.1016/j.oraloncology.2017.02.009
pubmed: 28351574
Liao DZ, Schlecht NF, Rosenblatt G, Kinkhabwala CM, Leonard JA, Ference RS et al (2019) Association of delayed time to treatment initiation with overall survival and recurrence among patients with head and neck squamous cell carcinoma in an underserved urban population. JAMA Otolaryngol—Head Neck Surg 145:1001–1009
doi: 10.1001/jamaoto.2019.2414
pubmed: 31513264
pmcid: 6743055
Boscolo-Rizzo P, Schroeder L, Romeo S, Pawlita M (2015) The prevalence of human papillomavirus in squamous cell carcinoma of unknown primary site metastatic to neck lymph nodes: a systematic review. Clin Exp Metastasis 32:835–845
doi: 10.1007/s10585-015-9744-z
pubmed: 26358913
Schroeder L, Boscolo-Rizzo P, Dal Cin E, Romeo S, Baboci L, Dyckhoff G et al (2017) Human papillomavirus as prognostic marker with rising prevalence in neck squamous cell carcinoma of unknown primary: a retrospective multicentre study. Eur J Cancer 74:73–81
doi: 10.1016/j.ejca.2016.12.020
pubmed: 28335889
Zengel P, Assmann G, Mollenhauer M, Jung A, Sotlar K, Kirchner T et al (2012) Cancer of unknown primary originating from oropharyngeal carcinomas are strongly correlated to HPV positivity. Virchows Arch Int J Pathol 461:283–290
doi: 10.1007/s00428-012-1290-3